Skip to content

The value of treating refractory secretory otitis media with acupuncture and traditional Chinese medicine at the same time

The value of treating refractory secretory otitis media with acupuncture and traditional Chinese medicine at the same time

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000003
Enrollment
Unknown
Registered
2024-01-10
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otitis Media with Effusion

Interventions

Experimental group:The combination of traditional Chinese medicine with western medicine therapy

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Adult refractory secretory otitis media patients, as follows: (1) Age 18-70 years old; (2) Patients diagnosed with OME through otoscopy, pure tone audiometry, and acoustic immittance examination, and their medical history was less than 3 months; (3) Eustachian tube pressure measurement score (TMM score) 0-1 score; (4) refusal of invasive treatment, and TCM syndrome differentiation for spleen deficiency and dampness syndrome; (5) Informed consent, can cooperate with treatment and follow-up, and sign informed consent

Exclusion criteria

Exclusion criteria: (1) fluctuating sensorineural deafness; (2) Otoscopy examination of tympanic membrane and promontory adhesion or external otitis (external ear canal exudation, fungal infection, etc.); (3) Abnormal opening of eustachian tube is clearly found; (4) Eligible for surgical treatment due to other nasal, sinus or ear diseases; (5) A history of middle ear, nasal cavity and nasopharyngeal surgery on the affected side; (6) A history of cleft palate or other malformations or related surgical repair; (7) A history of head or neck surgery or radiotherapy; (8) Patients with ciliary immobility syndrome; (9) The expected survival of malignant tumors was less than 12 months; (10) The investigator believes that the patient has other conditions that are not suitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Clinical response rate after 8 weeks of treatment;

Secondary

MeasureTime frame
A-B gap;ETDQ-7 score;Valsalva action;Clinical response rate after 2 weeks of treatment;Clinical response rate after 4 weeks of treatment;TMM score;

Countries

China

Contacts

Public ContactZhong Zhen

Peking University First Hospital

1341466115@qq.com13501284541

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026